Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-5401 + INO-9012 + Atezolizumab in Advanced Urothelial Carcinoma
NCT03502785Phase 2Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Jul 2018
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of INO-5401 and ino-9012 in urothelial carcinoma (UC) (2 cohorts), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs), Number of Participants With Clinically Significant Changes in Hematological Parameters and 4 more. Started Jul 2018; status: completed.
02
Drugs
INO-5401ino-9012
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03502785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502785.